Deciphering the oncogenic role and drug sensitivity of AC007731.5 in breast cancer
Letters in Drug Design & Discovery · 2026-11 · 100633
DOI: 10.1016/j.lddd.2026.100633 ↗Kurz gefasst
Fachartikel in der Zeitschrift Letters in Drug Design & Discovery, 2026-11. Verfasst von Yuhan Zheng und 5 weiteren Autor:innen. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
This study aims to investigate the role of long non-coding RNA ( lncRNA) AC007731.5 (the transcript from the FAM230G locus; FAM230G-201 is the main annotated transcript corresponding to AC007731.5) in breast cancer (BC) through an integrated bioinformatics approach combined with preliminary experimental validation.
Methods
The research utilized transcriptome data and clinical information from the The Cancer Genome Atlas (TCGA) breast cancer cohort, employing a comprehensive set of bioinformatics tools. These included differential expression analysis to identify significant lncRNA expression changes, Cox proportional hazards regression (COX) regression analysis for survival prediction, receiver operating characteristic (ROC) curves for diagnostic performance evaluation, Kaplan-Meier survival analysis to assess prognosis, Nomogram model construction for risk stratification, gene enrichment analysis to elucidate biological functions, immunoinformatics to analyze immune cell infiltration, and drug sensitivity analysis to evaluate therapeutic potential. quantitative real-time polymerase chain reaction (qRT-PCR) was applied to validate the expression levels of AC007731.5 in breast cancer cell lines. Cell proliferation and migration were measured using 5-ethynyl-2′-deoxyuridine (EdU) and Transwell assays. Furthermore, Cell Counting Kit-8 (CCK-8), flow cytometry, and western blots were applied to assess the effect of FAM230G-201 (the main transcript of AC007731.5) on Mitoxantrone sensitivity in breast cancer cells.
Results
AC007731.5 was an independent prognostic factor for BC in multivariate Cox regression (HR = 1.087, P = 0.012). However, its prognostic discriminatory ability was modest (time-dependent AUC = 0.618 for 5-year survival), indicating that it may serve as a candidate biomarker rather than a stand-alone clinical predictor. It exhibited elevated expression and was associated with poorer patient survival. Functional studies indicated its involvement in multiple amino acid metabolic processes, signaling pathways, and immune regulation, with an association with reduced activated dendritic cell infiltration. Furthermore, elevated AC007731.5 expression was associated with reduced sensitivity to six therapeutic compounds ( P < 0.05), including Alisertib, AZD5438, ERK2440, JAK18709, Mitoxantrone, and VSP348731. Consistently, FAM230G-201 silencing increased Mitoxantrone sensitivity in breast cancer cells ( P < 0.05).
Conclusion
AC007731.5 is associated with adverse prognosis in BC, although its discriminatory performance is modest (AUC = 0.618) and its clinical utility requires prospective validation.
Zitieren
APA
Zheng, Y., Chen, X., Liu, X., Zhou, Y., Yang, P., & Guan, C. (2026). Deciphering the oncogenic role and drug sensitivity of AC007731.5 in breast cancer. Letters in Drug Design & Discovery, 100633. https://doi.org/10.1016/j.lddd.2026.100633
Vancouver
Zheng Y, Chen X, Liu X, Zhou Y, Yang P, Guan C. Deciphering the oncogenic role and drug sensitivity of AC007731.5 in breast cancer. Letters in Drug Design & Discovery. 2026:100633. doi:10.1016/j.lddd.2026.100633
BibTeX
@article{Zheng2026,
author = {Zheng, Yuhan and Chen, Xinggui and Liu, Xuan and Zhou, Yijin and Yang, Pei and Guan, Chengnong},
title = {Deciphering the oncogenic role and drug sensitivity of AC007731.5 in breast cancer},
journal = {Letters in Drug Design & Discovery},
year = {2026},
pages = {100633},
doi = {10.1016/j.lddd.2026.100633}
}
EUVIMED